FindTrial
Sign In

GDC-0449

DRUG5 trials

Sponsors

Genentech, Inc., UCSF Benioff Children's Hospital Oakland, Lisa Bax

Conditions

Basal Cell Nevus SyndromeGorlin SyndromeHealthy VolunteerPancreatic Ductal AdenocarcinomaSolid CancersUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
CompletedNCT00607724
Genentech, Inc.Unspecified Adult Solid Tumor, Protocol Specific
Start: 2007-04-30End: 2009-11-30Updated: 2015-10-08
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
CompletedNCT00968981
Genentech, Inc.Solid Cancers
Start: 2009-09-30End: 2010-10-31Updated: 2017-07-11
A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects
CompletedNCT01173536
Genentech, Inc.Healthy Volunteer
Start: 2010-08-25End: 2011-03-18Updated: 2017-02-17

Phase 2

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
CompletedNCT00957229
UCSF Benioff Children's Hospital OaklandBasal Cell Nevus Syndrome, Gorlin Syndrome
Start: 2009-08-31End: 2014-01-31Updated: 2021-01-11
Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)
TerminatedNCT01096732
Lisa BaxPancreatic Ductal Adenocarcinoma
Start: 2011-02-28End: 2012-08-31Updated: 2014-01-08

Related Papers

CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosis
Thorax2017-03-0160 citations
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
2016-11-1086 citations
P23 Target And Biomarker Discovery For Hedgehog Pathway Activity In Idiopathic Pulmonary Fibrosis In Support Of A Phase 2 Randomised, Double-blind, Placebo-controlled Study To Assess Efficacy And Safety Of Vismodegib In Ipf (island)
Thorax2014-11-10
Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Journal of Clinical Oncology2014-05-205 citations
The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome.
2014-05-0129 citations
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
2012-06-01367 citations
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
2009-09-02760 citations